Implantable Pump + Electrical Stimulator for Heart Failure Recovery

So Patient May Keep Their Own Heart Instead of Getting a Transplant

Howard J. Leonhardt – BioLeonhardt Stem Cell Pump + Stimulator and MyoStim Pacers, Inc. ; 1531 6th Street, Unit 401 Santa Monica, California

We have learned over the past 30 years just how difficult it is to fully recover a failing heart. CHF drugs achieve no improvement in exercise capacity in these patients with minus 4 meters decline results. CRT ICD pacers achieve 16 to 20 meters improvement. Single time non-myogenic stem cell autologous injections achieve about 53 meters improvement. Allogenic non-myogenic cells 10 meters improvement. Single time myogenic cell injections achieve 95.7 meters improvement over placebo. This new device which is combination implantable, re-fillable, programmable pump plus a programmable microcurrent stimulator is expected to achieve > 230 meters improvement. The therapeutic protocol includes a multi-stage approach to full heart recovery 1. Pre-treat heart scar. 2. Treat heart scar. 3. Post treatment maintenance and Repeat until all myocardial scar tissue is fully 100% converted to beating pumping muscle the the left ventricle has reverse remodeled back to its original pre-heart failure dimensions and function. The protocol includes growth factors, cells, hyrogels, genes and stimulation signals for 1. Growing new blood vessels – VEGF. 2. Maturing blood vessels and increasing their inner diameter – SDF-1. 3. Recruiting stem cells via a homing signal – SDF-1. 4. Proliferating cells including resident cardiomyocytes. 5. Differentiating recruited stem cells into beating bumping muscle. 6. Releasing hepatocyte growth factor to reduce risk of arrhythmia’s. 7. Ensuring newly formed muscle beats in synchrony with host muscle. The device is implanted in the abdomen of the patient and is fully programmable and re-fillable. Over the course of one year a Class III failing heart can be fully regenerated and the patient can be fully cured 100% of heart failure with no further hospitalizations. Over a dozen related pre-clinical studies support this develo